{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:54:37Z","timestamp":1780412077617,"version":"3.54.1"},"reference-count":161,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T00:00:00Z","timestamp":1579910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40263-020-00698-5","type":"journal-article","created":{"date-parts":[[2020,1,25]],"date-time":"2020-01-25T11:02:28Z","timestamp":1579950148000},"page":"147-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacological Management of the Genetic Generalised Epilepsies in Adolescents and Adults"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9279-0665","authenticated-orcid":false,"given":"Linda J.","family":"Stephen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Brodie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,25]]},"reference":[{"key":"698_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40263-016-0406-8","volume":"31","author":"MJ Brodie","year":"2017","unstructured":"Brodie MJ. Tolerability and safety of commonly used antiepileptic drugs in adolescents and adults: a clinician\u2019s overview. CNS Drugs. 2017;31:135\u201347.","journal-title":"CNS Drugs"},{"key":"698_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","volume":"58","author":"IE Scheffer","year":"2017","unstructured":"Scheffer IE, Berkovic S, Capovilla G, et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia. 2017;58:512\u201321.","journal-title":"Epilepsia."},{"key":"698_CR3","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1474-4422(18)30173-X","volume":"17","author":"P Striano","year":"2018","unstructured":"Striano P, Nobile C. The genetic basis of juvenile myoclonic epilepsy. Lancet Neurol. 2018;17:493\u20135.","journal-title":"Lancet Neurol."},{"key":"698_CR4","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa0902014","volume":"362","author":"TA Glauser","year":"2010","unstructured":"Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy. New Engl J Med. 2010;362:790\u20139.","journal-title":"New Engl J Med."},{"key":"698_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0920-1211(97)00080-6","volume":"29","author":"SI Wallace","year":"1998","unstructured":"Wallace SI. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147\u201354.","journal-title":"Epilepsy Res"},{"key":"698_CR6","unstructured":"Ethosuximide; indications and dose. In: National Institute for Health and Care Excellence. British National Formulary. https:\/\/bnf.nice.org.uk\/drug\/ethosuximide.html#indicationsAndDoses. Accessed 15 Dec 2019."},{"key":"698_CR7","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/epi.12074","volume":"54","author":"T Glauser","year":"2013","unstructured":"Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54:551\u201363.","journal-title":"Epilepsia."},{"key":"698_CR8","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","volume":"69","author":"SF Berkovic","year":"2007","unstructured":"Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalised epilepsy. Neurology. 2007;69:1751\u201360.","journal-title":"Neurology."},{"key":"698_CR9","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1212\/WNL.0000000000001930","volume":"85","author":"JA French","year":"2015","unstructured":"French JA, Krauss G, Wechsler R, et al. Adjunctive perampanel for treatment of drug-resistant primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy: a double-blind randomized placebo-controlled phase III trial. Neurology. 2015;85:950\u20137.","journal-title":"Neurology."},{"key":"698_CR10","doi-asserted-by":"crossref","unstructured":"Yamauchi T, Aikawa H. Efficacy of zonisamide: our experience. Seizure. 2004;(Suppl. 1):S41\u20138.","DOI":"10.1016\/j.seizure.2004.04.021"},{"key":"698_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1684\/epd.2009.0239","volume":"11","author":"A Marinas","year":"2009","unstructured":"Marinas A, Villaneuva V, Giraldez BG, et al. Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy. Epileptic Disord. 2009;11:61\u20136.","journal-title":"Epileptic Disord."},{"key":"698_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.yebeh.2010.01.016","volume":"17","author":"LJ Stephen","year":"2010","unstructured":"Stephen LJ, Kelly K, Wilson EA, Parker P, Brodie MJ. A prospective audit of adjunctive zonisamide in an everyday clinical setting. Epilepsy Behav. 2010;17:455\u201360.","journal-title":"Epilepsy Behav"},{"key":"698_CR13","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.eplepsyres.2014.04.010","volume":"7","author":"R Velizarova","year":"2014","unstructured":"Velizarova R, Crespel A, Genton P. Zonisamide for refractory juvenile absence epilepsy. Epilepsy Res. 2014;7:1263\u20136.","journal-title":"Epilepsy Res"},{"key":"698_CR14","first-page":"346","volume":"176","author":"D Janz","year":"1957","unstructured":"Janz D, Christian W. Impulsive petit mal. Deutsche Zeitschrift f\u00fcr Nervenheilkunde. 1957;176:346\u201388.","journal-title":"Deutsche Zeitschrift f\u00fcr Nervenheilkunde."},{"key":"698_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.yebeh.2018.01.039","volume":"82","author":"SD Shorvon","year":"2018","unstructured":"Shorvon SD, Bermejo PE, Gibbs AA, Huberfeld G, Kalviainen R. Antiepileptic drug treatment of generalized tonic-clonic seizures: an evaluation of regulatory data and five criteria for drug selection. Epilepsy Behav. 2018;82:91\u2013103.","journal-title":"Epilepsy Behav"},{"key":"698_CR16","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1517\/14656566.2013.800045","volume":"14","author":"P Striano","year":"2013","unstructured":"Striano P, Belcastro V. Treating mycolonic epilepsy in children: state of the art. Exp Opin Pharmacother. 2013;14:1355\u201361.","journal-title":"Exp Opin Pharmacother."},{"key":"698_CR17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1212\/01.wnl.0000271385.85302.55","volume":"69","author":"DG Kasteleijn-Nolst Trenite","year":"2007","unstructured":"Kasteleijn-Nolst Trenite DG, Genton P, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology. 2007;69:1027\u201334.","journal-title":"Neurology."},{"key":"698_CR18","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1038\/bjp.2008.198","volume":"154","author":"A Matagne","year":"2008","unstructured":"Matagne A, Margineau DG, Kenda B, et al. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 2008;154:1662\u201371.","journal-title":"Br J Pharmacol"},{"key":"698_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/epi.12391","volume":"55","author":"P Kwan","year":"2014","unstructured":"Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia. 2014;55:38\u201346.","journal-title":"Epilepsia."},{"key":"698_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","volume":"51","author":"AT Berg","year":"2015","unstructured":"Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organisation of the epilepsies: report of the ILAE Commission on Classification and Terminology. Epilepsia. 2015;51:676\u201385.","journal-title":"Epilepsia."},{"key":"698_CR21","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1080\/14656566.2019.1617850","volume":"20","author":"G Balagura","year":"2019","unstructured":"Balagura G, Lapadre G, Verrotti A, Striano P. Moving beyond sodium valproate: choosing the right anti-epileptic drug in children. Exp Opin Pharmacother. 2019;20:1449\u201356.","journal-title":"Exp Opin Pharmacother."},{"key":"698_CR22","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0163-7258(01)00122-X","volume":"90","author":"P Kwan","year":"2001","unstructured":"Kwan P, Sills GJ, Brodie MJ. The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther. 2001;90:21\u201334.","journal-title":"Pharmacol Ther"},{"key":"698_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S1474-4422(15)00314-2","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E. Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug. Lancet Neurol. 2016;15:210\u20138.","journal-title":"Lancet Neurol."},{"key":"698_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","volume":"17","author":"T Tomson","year":"2018","unstructured":"Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Perucca E. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17:530\u20138.","journal-title":"Lancet Neurol."},{"key":"698_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","volume":"2","author":"PN Patsalos","year":"2003","unstructured":"Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473\u201381.","journal-title":"Lancet Neurol."},{"key":"698_CR26","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.seizure.2013.07.006","volume":"22","author":"RA Machado","year":"2013","unstructured":"Machado RA, Garcia VF, Astencio AG, Cuartas VB. Efficacy and tolerability of lamotrigine in juvenile myoclonic epilepsy: a prospective, unblinded randomized controlled trial. Seizure. 2013;22:846\u201355.","journal-title":"Seizure."},{"key":"698_CR27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1080\/14737175.2016.1179113","volume":"16","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ. Modern management of juvenile myoclonic epilepsy. Expert Rev Neurother. 2016;16:681\u20138.","journal-title":"Expert Rev Neurother"},{"key":"698_CR28","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","volume":"26","author":"MJ Brodie","year":"1997","unstructured":"Brodie MJ, Yuen AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997;26:423\u201332.","journal-title":"Epilepsy Res"},{"key":"698_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-017-0441-0","volume":"31","author":"MJ Brodie","year":"2017","unstructured":"Brodie MJ. Sodium channel blockers in the treatment of epilepsy. CNS Drugs. 2017;31:527\u201334.","journal-title":"CNS Drugs"},{"key":"698_CR30","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1528-1157.1999.tb00807.x","volume":"40","author":"AH Guberman","year":"1999","unstructured":"Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine associated rash: risk benefit comorbidities in adults and children. Epilepsia. 1999;40:985\u201391.","journal-title":"Epilepsia."},{"key":"698_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.contraception.2010.06.013","volume":"83","author":"ME Gaffield","year":"2011","unstructured":"Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception. 2011;83:16\u201329.","journal-title":"Contraception."},{"key":"698_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1006\/phrs.1997.0124","volume":"35","author":"EA Perucca","year":"1997","unstructured":"Perucca EA. Pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res. 1997;35:241\u201356.","journal-title":"Pharmacol Res"},{"key":"698_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1046\/j.1528-1157.2003.27402.x","volume":"44","author":"S Lee","year":"2003","unstructured":"Lee S, Sziklas V, Andermann F, et al. The effect of adjunctive topiramate on cognitive function in patients with epilepsy. Epilepsia. 2003;44:339\u201347.","journal-title":"Epilepsia."},{"key":"698_CR34","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1046\/j.1528-1157.2003.05402.x","volume":"44","author":"M Mula","year":"2003","unstructured":"Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003;44:659\u201363.","journal-title":"Epilepsia."},{"key":"698_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00415-013-7239-x","volume":"261","author":"G Veiby","year":"2014","unstructured":"Veiby G, Daltveit AK, Engelsen BA, Gilhus NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261:579\u201388.","journal-title":"J Neurol"},{"key":"698_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1528-1167.2012.03671.x","volume":"54","author":"MJ Brodie","year":"2013","unstructured":"Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia. 2013;54:11\u201327.","journal-title":"Epilepsia."},{"key":"698_CR37","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1528-1157.1997.tb01123.x","volume":"38","author":"WE Rosenfield","year":"1997","unstructured":"Rosenfield WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyloestradiol. Epilepsia. 1997;38:317\u201323.","journal-title":"Epilepsia."},{"key":"698_CR38","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1517\/14728214.12.3.407","volume":"12","author":"P Kwan","year":"2007","unstructured":"Kwan P, Brodie MJ. Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007;12:407\u201322.","journal-title":"Expert Opin Emerg Drugs."},{"key":"698_CR39","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1212\/01.WNL.0000091865.46063.67","volume":"61","author":"JR White","year":"2003","unstructured":"White JR, Walczak TS, Leppik IE, et al. Discontinuation of levetiracetam because of behavioural side effects. Neurology. 2003;61:1218\u201321.","journal-title":"Neurology."},{"key":"698_CR40","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1111\/j.1528-1167.2007.01043.x","volume":"48","author":"LJ Hirsch","year":"2007","unstructured":"Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia. 2007;48:1351\u20139.","journal-title":"Epilepsia."},{"key":"698_CR41","first-page":"546","volume-title":"The treatment of epilepsy","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ. Perampanel. In: Shorvon S, Perucca E, Engel J, editors. The treatment of epilepsy. 4th ed. Hoboken: Wiley-Blackwell; 2016. p. 546\u201354.","edition":"4"},{"key":"698_CR42","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/epi.12212","volume":"54","author":"BJ Steinhoff","year":"2013","unstructured":"Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54:1481\u20139.","journal-title":"Epilepsia."},{"key":"698_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.yebeh.2015.11.002","volume":"54","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Stephen LJ. Prospective audit with adjunctive perampanel: preliminary observations in focal epilepsy. Epilepsy Behav. 2016;54:100\u20133.","journal-title":"Epilepsy Behav"},{"key":"698_CR44","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1111\/epi.13054","volume":"56","author":"AB Ettinger","year":"2015","unstructured":"Ettinger AB, Lopresti A, Yang H, et al. Psychiatric and behavioural adverse events in randomized clinical studies of the non-competitive AMPA receptor antagonist perampanel. Epilepsia. 2015;56:1252\u201363.","journal-title":"Epilepsia."},{"key":"698_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000001558","volume":"84","author":"BE Gidal","year":"2015","unstructured":"Gidal BE, Laurenza A, Hussein Z, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1\u20139.","journal-title":"Neurology."},{"key":"698_CR46","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/0920-1211(89)90041-7","volume":"3","author":"DM Rock","year":"1989","unstructured":"Rock DM, Macdonald RL, Taylor CP. Blockade of sustained repetitive action potentials in cultured spinal cord neurons by zonisamide (AD 810, CI 912), a novel anticonvulsant. Epilepsy Res. 1989;3:138\u201343.","journal-title":"Epilepsy Res"},{"key":"698_CR47","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1059-1311(96)80104-X","volume":"5","author":"M Kito","year":"1996","unstructured":"Kito M, Machara M, Watanabe K. Mechanisms of T-type calcium channel blockade by zonisamide. Seizure. 1996;5:115\u20139.","journal-title":"Seizure."},{"key":"698_CR48","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2165\/11599780-000000000-00000","volume":"26","author":"J Piedad","year":"2012","unstructured":"Piedad J, Rickards H, Besag FG, Cavana AE. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy. CNS Drugs. 2012;26:319\u201335.","journal-title":"CNS Drugs"},{"key":"698_CR49","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1185\/030079907X210499","volume":"23","author":"S Wroe","year":"2007","unstructured":"Wroe S. Zonisamide and renal calculi in patients with epilepsy: how big an issue? Curr Med Res Opin. 2007;23:1765\u201373.","journal-title":"Curr Med Res Opin"},{"key":"698_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.eplepsyres.2004.06.009","volume":"62","author":"PA Low","year":"2004","unstructured":"Low PA, James S, Peschel T, Leon R, Rothstein A. Zonisamide and associated oligohydrosis and hypothermia. Epilepsy Res. 2004;62:27\u201334.","journal-title":"Epilepsy Res"},{"key":"698_CR51","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1527-3458.2007.00009.x","volume":"13","author":"MJ Goren","year":"2007","unstructured":"Goren MJ, Onat F. Ethosuximide: from bench to bedside. CNS Drugs. 2007;13:224\u201339.","journal-title":"CNS Drugs"},{"issue":"Suppl. 8","key":"698_CR52","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/epi.12027","volume":"53","author":"MJ Brodie","year":"2012","unstructured":"Brodie MJ, Kwan P. Current position of phenobarbital in epilepsy and its future. Epilepsia. 2012;53(Suppl. 8):40\u20136.","journal-title":"Epilepsia."},{"key":"698_CR53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1684\/epd.2014.0714","volume":"16","author":"G Zaccara","year":"2014","unstructured":"Zaccara G, Perucca E. Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs. Epileptic Disord. 2014;16:403\u201332.","journal-title":"Epileptic Disord."},{"key":"698_CR54","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4081\/pr.2016.6516","volume":"8","author":"M Pernea","year":"2016","unstructured":"Pernea M, Sutcliffe AG. Clobazam and its use in epilepsy. Pediatr Rep. 2016;8:34\u20138.","journal-title":"Pediatr Rep."},{"key":"698_CR55","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","volume":"26","author":"R Sankar","year":"2012","unstructured":"Sankar R. GABA (A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs. 2012;26:229\u201344.","journal-title":"CNS Drugs"},{"key":"698_CR56","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.nurt.2006.11.002","volume":"4","author":"Y Ng","year":"2007","unstructured":"Ng Y, Collins SD. Clobazam. Neurotherapeutics. 2007;4:138\u201344.","journal-title":"Neurotherapeutics."},{"key":"698_CR57","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/cns.12399","volume":"21","author":"AC Gauthier","year":"2015","unstructured":"Gauthier AC, Mattson RH. Clobazam: a safe, efficacious and newly rediscovered therapeutic for epilepsy. CNS Neurosci Ther. 2015;21:543\u20138.","journal-title":"CNS Neurosci Ther"},{"key":"698_CR58","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1056\/NEJM197810122991505","volume":"299","author":"T Browne","year":"1978","unstructured":"Browne T. Clonazepam. N Engl J Med. 1978;299:812\u20136.","journal-title":"N Engl J Med"},{"key":"698_CR59","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.eplepsyres.2016.04.003","volume":"123","author":"MJ Brodie","year":"2016","unstructured":"Brodie MJ, Chung S, Wade A, et al. Clobazam and clonazepam use in epilepsy: results from a UK database incident user cohort study. Epilepsy Res. 2016;123:68\u201374.","journal-title":"Epilepsy Res"},{"key":"698_CR60","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.yebeh.2005.12.005","volume":"8","author":"A Grabowska-Grzb","year":"2006","unstructured":"Grabowska-Grzb A, Jedrzcejczak J, Naganska E, Fizer U. Risk factors for depression in people with epilepsy. Epilepsy Behav. 2006;8:411\u20137.","journal-title":"Epilepsy Behav"},{"key":"698_CR61","first-page":"1","volume":"11","author":"LJ Stephen","year":"2017","unstructured":"Stephen LJ, Brodie MJ. Brivaracetam: a novel antiepileptic drug for focal-onset seizure. Therap Adv Neurol Dis. 2017;11:1\u201310.","journal-title":"Therap Adv Neurol Dis."},{"key":"698_CR62","first-page":"34","volume":"664","author":"M Gillard","year":"2011","unstructured":"Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anticonvulsant properties. Br J Pharmacol. 2011;664:34\u201344.","journal-title":"Br J Pharmacol"},{"key":"698_CR63","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","volume":"52","author":"SL Yates","year":"2015","unstructured":"Yates SL, Fakhoury T, Lang W, Eckhardt K, Borghs S, D\u2019Souza J. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav. 2015;52:165\u20138.","journal-title":"Epilepsy Behav"},{"key":"698_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.seizure.2016.11.008","volume":"45","author":"L Zhu","year":"2017","unstructured":"Zhu L, Chen D, Tao C, Xu D, Chen S, Liu L. The adverse event profile of brivaracetam: a meta-analysis of randomized controlled trials. Seizure. 2017;45:7\u201316.","journal-title":"Seizure."},{"key":"698_CR65","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/9781118936979.ch31","volume-title":"The treatment of epilepsy","author":"J D\u2019Souza","year":"2015","unstructured":"D\u2019Souza J, Perucca E. Brivaracetam. In: Shorvon S, Perucca E, Engel J, editors. The treatment of epilepsy. 4th ed. Chichester: Wiley; 2015. p. 418\u201330.","edition":"4"},{"key":"698_CR66","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1016\/S0140-6736(07)60461-9","volume":"369","author":"AG Marson","year":"2007","unstructured":"Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369:1016\u201326.","journal-title":"Lancet"},{"key":"698_CR67","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1136\/jnnp-2011-301999","volume":"83","author":"F Rosenow","year":"2012","unstructured":"Rosenow F, Schade-Brittinger C, Burchardi N, et al. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26\u00a0weeks of monotherapy for focal and generalised epilepsy: an open-label, prospective, randomised controlled multicenter study. J Neurol Neurosurg Psychiatry. 2012;83:1093\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"698_CR68","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1080\/14656566.2017.1328499","volume":"18","author":"G Coppola","year":"2017","unstructured":"Coppola G, Piccorossi A, Operto FF, Verrotti A. Anticonvulsant drugs for generalized tonic-clonic epilepsy. Exp Opin Pharmacother. 2017;18:925\u201336.","journal-title":"Exp Opin Pharmacother."},{"key":"698_CR69","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/epi.12028","volume":"54","author":"TA Glauser","year":"2013","unstructured":"Glauser TA, Cnaan A, Shinnar S, et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia. 2013;54:141\u201355.","journal-title":"Epilepsia."},{"key":"698_CR70","doi-asserted-by":"crossref","unstructured":"Brigo F, Igwe SC, Lattanzi S. Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database Syst Rev. 2019;2:CD003032.","DOI":"10.1002\/14651858.CD003032.pub4"},{"key":"698_CR71","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/0883073818811511","volume":"34","author":"D Nolan","year":"2018","unstructured":"Nolan D, Lester S, Rau S, et al. Clinical use and efficacy of levetiracetam for absence epilepsies. J Child Neurol. 2018;34:94\u20138.","journal-title":"J Child Neurol"},{"key":"698_CR72","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11940-016-0404-7","volume":"18","author":"A Levy","year":"2016","unstructured":"Levy A, Chen R. Myoclonus: pathophysiology and treatment options. Curr Treat Options Neurol. 2016;18:21.","journal-title":"Curr Treat Options Neurol."},{"key":"698_CR73","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/epi4.12321","volume":"4","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen J, Ren J, et al. Clinical features and treatment outcomes of juvenile myoclonic epilepsy patients. Epilepsia Open. 2019;4:302\u20138.","journal-title":"Epilepsia Open."},{"key":"698_CR74","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.eplepsyres.2014.04.010","volume":"108","author":"R Velizarova","year":"2014","unstructured":"Velizarova R, Crespel A, Genton P, Serafini A, Gelisse P. Zonisamide for refractory juvenile absence epilepsy. Epilepsy Res. 2014;108:1263\u20136.","journal-title":"Epilepsy Res"},{"key":"698_CR75","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1111\/epi.13768","volume":"58","author":"I Steinig","year":"2017","unstructured":"Steinig I, von Podwils F, M\u00f6ddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia. 2017;58:1208\u201316.","journal-title":"Epilepsia."},{"key":"698_CR76","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1684\/epd.2017.0939","volume":"20","author":"A Grande-Martin","year":"2018","unstructured":"Grande-Martin A, Sopelana-Garay D, Pardal-Fernandez J, et al. Exceptional response to brivaracetam in a patient with refractory idiopathic generalized epilepsy and absence seizures. Epileptic Disord. 2018;20:60\u20134.","journal-title":"Epileptic Disord."},{"key":"698_CR77","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1111\/epi.14476","volume":"59","author":"A Strzelczyk","year":"2018","unstructured":"Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus. Epilepsia. 2018;59:1549\u201356.","journal-title":"Epilepsia."},{"key":"698_CR78","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/ane.12935","volume":"138","author":"PS Reif","year":"2018","unstructured":"Reif PS, M\u00e4nner A, Willems LM, et al. Intravenous lacosamide for treatment of absence status epilepticus in genetic generalized epilepsy: a case report and review of literature. Acta Neurol Scand. 2018;138:259\u201362.","journal-title":"Acta Neurol Scand"},{"issue":"Suppl. 1","key":"698_CR79","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1016\/j.yebeh.2012.06.024","volume":"28","author":"CS Camfield","year":"2013","unstructured":"Camfield CS, Striano P, Camfield PR. Epidemiology of juvenile myoclonic epilepsy. Epilepsy Behav. 2013;28(Suppl. 1):S15\u20137.","journal-title":"Epilepsy Behav"},{"key":"698_CR80","first-page":"1201","volume":"2","author":"M Maguire","year":"2012","unstructured":"Maguire M, Marson AG, Ramaratnam S. Epilepsy (generalised). Clin Evid. 2012;2:1201.","journal-title":"Clin Evid."},{"key":"698_CR81","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1528-1157.1982.tb05085.x","volume":"23","author":"A Covanis","year":"1982","unstructured":"Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia. 1982;23:693\u2013720.","journal-title":"Epilepsia."},{"key":"698_CR82","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/S1059-1311(00)90530-2","volume":"10","author":"S Calleja","year":"2001","unstructured":"Calleja S, Salas-Puig J, Ribacoba R, et al. Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. Seizure. 2001;10:424\u20137.","journal-title":"Seizure."},{"issue":"Suppl. 9","key":"698_CR83","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1528-1167.2005.00327.x","volume":"4","author":"N Hitiris","year":"2005","unstructured":"Hitiris N, Brodie MJ. Evidence based treatment of idiopathic generalized epilepsies with older antiepileptic drugs. Epilepsia. 2005;4(Suppl. 9):149\u201353.","journal-title":"Epilepsia."},{"key":"698_CR84","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1053\/seiz.2001.0662","volume":"11","author":"MM Mendriatta","year":"2002","unstructured":"Mendriatta MM, Aggarwal P. Clinical expression and EEG features of patients with juvenile myoclonic epilepsy (JME) from North India. Seizure. 2002;11:431\u20136.","journal-title":"Seizure."},{"key":"698_CR85","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eplepsyres.2015.11.012","volume":"119","author":"A Chowdhury","year":"2016","unstructured":"Chowdhury A, Brodie MJ. Pharmacological outcomes in juvenile myoclonic epilepsy over a 30\u00a0year period: support for sodium valproate. Epilepsy Res. 2016;119:62\u20136.","journal-title":"Epilepsy Res"},{"key":"698_CR86","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/jnnp.70.2.240","volume":"70","author":"P Gelisse","year":"2001","unstructured":"Gelisse P, Genton P, Thomas P, et al. Clinical factors of drug resistance in juvenile myoclonic epilepsy. J Neurol Neurosurg Psychiatry. 2001;70:240\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"698_CR87","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.seizure.2014.03.017","volume":"23","author":"S Jayalakshmi","year":"2014","unstructured":"Jayalakshmi S, Vooturi S, Bana AK, et al. Factors associated with lack of response to valproic acid monotherapy in juvenile myoclonic epilepsy. Seizure. 2014;23:527\u201332.","journal-title":"Seizure."},{"key":"698_CR88","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/epi4.12349","volume":"4","author":"K Silvennoinen","year":"2019","unstructured":"Silvennoinen K, de Lange N, Zagaglia S, et al. Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open. 2019;4:420\u201330.","journal-title":"Epilepsia Open."},{"key":"698_CR89","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.yebeh.2007.03.003","volume":"10","author":"PM Levisohn","year":"2007","unstructured":"Levisohn PM, Holland KD. Topiramate or valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison. Epilepsy Behav. 2007;10:547\u201352.","journal-title":"Epilepsy Behav"},{"key":"698_CR90","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.jocn.2012.10.020","volume":"20","author":"KM Park","year":"2013","unstructured":"Park KM, Kim SH, Nho SK, et al. A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy. J Clin Neurosci. 2013;20:1079\u201382.","journal-title":"J Clin Neurosci."},{"key":"698_CR91","doi-asserted-by":"publisher","unstructured":"Liu J, Wang LN, Wang YP. Topiramate for juvenile myoclonic epilepsy. Cochrane Database Syst Rev. 2019;1:CD010008. https:\/\/doi.org\/10.1002\/14651858.cd010008.pub4.","DOI":"10.1002\/14651858.cd010008.pub4"},{"key":"698_CR92","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","volume":"70","author":"S Noachter","year":"2008","unstructured":"Noachter S, Andermann E, Meyisck P, et al. Levetiracetam for the treatment of idiopathic generalised epilepsy with myoclonic seizures. Neurology. 2008;70:607\u201316.","journal-title":"Neurology."},{"key":"698_CR93","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.eplepsyres.2009.02.016","volume":"85","author":"WE Rosenfeld","year":"2009","unstructured":"Rosenfeld WE, Benbadis S, Edrich P, et al. Levetiracetam as add on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized double-blind placebo-controlled studies. Epilepsy Res. 2009;85:72\u201380.","journal-title":"Epilepsy Res"},{"key":"698_CR94","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.eplepsyres.2006.05.013","volume":"17","author":"LM Specchio","year":"2006","unstructured":"Specchio LM, Gambardella A, Giallonardo AT, et al. Open label, long-term pragmatic study of levetiracetam in the treatment of juvenile myoclonic epilepsy. Epilepsy Res. 2006;17:32\u20139.","journal-title":"Epilepsy Res"},{"key":"698_CR95","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.seizure.2011.04.004","volume":"20","author":"LJ Stephen","year":"2011","unstructured":"Stephen LJ, Kelly K, Parker P, et al. Levetiracetam monotherapy outcomes from an epilepsy clinic. Seizure. 2011;20:554\u20137.","journal-title":"Seizure."},{"key":"698_CR96","doi-asserted-by":"crossref","unstructured":"Biton V, Bourgeois BF; YTC\/YTCE Study Investigators. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol. 2005;62:170\u20138.","DOI":"10.1001\/archneur.62.11.1705"},{"key":"698_CR97","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.yebeh.2006.01.016","volume":"3","author":"GM De Araujo Filho","year":"2006","unstructured":"De Araujo Filho GM, Pascalicchio TF, Lin K, Sousa PS, Yacubian MT. Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate. Epilepsy Behav. 2006;3:606\u20139.","journal-title":"Epilepsy Behav"},{"key":"698_CR98","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1528-1157.2000.tb00282.x","volume":"41","author":"LJ Stephen","year":"2000","unstructured":"Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective, observational study. Epilepsia. 2000;41:977\u201380.","journal-title":"Epilepsia."},{"key":"698_CR99","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1684\/j.1950-6945.2004.tb00075.x","volume":"6","author":"SV Kothare","year":"2004","unstructured":"Kothare SV, Valencia I, Khurana DS, et al. Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord. 2004;6:267\u201370.","journal-title":"Epileptic Disord."},{"key":"698_CR100","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.seizure.2011.12.010","volume":"21","author":"P Afra","year":"2012","unstructured":"Afra P, Adamolekum B. Lacosamide treatment of juvenile myoclonic epilepsy. Seizure. 2012;21:202\u20134.","journal-title":"Seizure."},{"key":"698_CR101","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.yebeh.2011.10.023","volume":"23","author":"A Zangaladze","year":"2012","unstructured":"Zangaladze A, Skidmore C. Lacosamide use in refractory idiopathic refractory primary generalized epilepsy. Epilepsy Behav. 2012;23:79\u201380.","journal-title":"Epilepsy Behav"},{"key":"698_CR102","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.eplepsyres.2016.12.015","volume":"130","author":"RT Wechsler","year":"2017","unstructured":"Wechsler RT, Yates SL, Messenheimer J, Leroy R, Beller C, Doty P. Lacosamide for uncontrolled primary generalized tonic-clonic seizures: an open-label study with 59-week extension. Epilepsy Res. 2017;130:13\u201320.","journal-title":"Epilepsy Res"},{"key":"698_CR103","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1007\/s00415-014-7487-4","volume":"261","author":"U Sodemann","year":"2014","unstructured":"Sodemann U, Moller HS, Blaabjerg M, Beier CP. Successful treatment of refractory absence status epilepticus with lacosamide. J Neurol. 2014;261:2025\u20137.","journal-title":"J Neurol"},{"key":"698_CR104","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.seizure.2013.12.004","volume":"23","author":"G D\u2019Orsi","year":"2014","unstructured":"D\u2019Orsi G, Pacillo T, Trivisano M, Pascarella MG, Ferrara MA, Specchio LM. Lacosamide in absence status epilepticus. Seizure. 2014;23:397\u20138.","journal-title":"Seizure."},{"key":"698_CR105","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1111\/j.1528-1157.1989.tb05479.x","volume":"30","author":"T Obeid","year":"1989","unstructured":"Obeid T, Panayiotopoulos CP. Clonazepam in juvenile myoclonic epilepsy. Epilepsia. 1989;30:603\u20136.","journal-title":"Epilepsia."},{"key":"698_CR106","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1212\/WNL.40.11.1677","volume":"40","author":"SR Resor","year":"1990","unstructured":"Resor SR, Resor LD. Chronic acetazolamide monotherapy in the treatment of juvenile myoclonic epilepsy. Neurology. 1990;40:1677\u201381.","journal-title":"Neurology."},{"key":"698_CR107","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/S1059-1311(03)00147-X","volume":"13","author":"M Ng","year":"2004","unstructured":"Ng M, Devinsky O. Vagus nerve stimulation for refractory idiopathic generalised epilepsy. Seizure. 2004;13:176\u20138.","journal-title":"Seizure."},{"key":"698_CR108","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.seizure.2003.09.002","volume":"13","author":"MD Holmes","year":"2004","unstructured":"Holmes MD, Silbergeld DL, Drouhard D, Wilensky JA, Ojemann L. Effect of vagus nerve stimulation on adults with pharmacoresistant generalized epilepsy syndromes. Seizure. 2004;13:340\u20135.","journal-title":"Seizure."},{"key":"698_CR109","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1212\/WNL.55.11.1757","volume":"55","author":"A Biraben","year":"2000","unstructured":"Biraben A, Allain H, Scarabin JM, et al. Exacerbation of juvenile myoclonic epilepsy with lamotrigine. Neurology. 2000;55:1757\u20138.","journal-title":"Neurology."},{"key":"698_CR110","unstructured":"Scottish Intercollegiate Guideline Network. Epilepsy and women\u2019s health. In: Diagnosis and management of epilepsy in adults (SIGN publication no 143). May 2015. http:\/\/www.sign.ac.uk\/assets\/sign143.pdf. Accessed 15 Dec 2019."},{"key":"698_CR111","unstructured":"National Institute for Health and Care Excellence. Epilepsies: diagnosis and management. Clinical guideline. January 2012. https:\/\/www.nice.org.uk\/guidance\/cg137\/resources\/epilepsies-diagnosis-and-management-pdf-35109515407813. Accessed 15 Dec 2019."},{"key":"698_CR112","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1017\/S0012162206000843","volume":"48","author":"NA Gayatri","year":"2006","unstructured":"Gayatri NA. Aggravation of epilepsy by anti-epileptic drugs. Dev Med Child Neurol. 2006;48:394\u20138.","journal-title":"Dev Med Child Neurol"},{"key":"698_CR113","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1053\/seiz.2001.0568","volume":"11","author":"S-I Hamano","year":"2002","unstructured":"Hamano S-I, Mochizuki M, Monikawa T. Phenobarbital-induced atypical absence seizure in benign childhood epilepsy with centrotemporal spikes. Seizure. 2002;11:201\u20134.","journal-title":"Seizure."},{"key":"698_CR114","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.pediatrneurol.2005.03.001","volume":"4","author":"M Sazgar","year":"2005","unstructured":"Sazgar M, Bourgeois B. Aggravation of epilepsy by antiepileptic drugs. Pediatr Neurol. 2005;4:227\u201334.","journal-title":"Pediatr Neurol"},{"key":"698_CR115","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.eplepsyres.2011.09.008","volume":"98","author":"LJ Stephen","year":"2012","unstructured":"Stephen LJ, Forsyth M, Kelly K, Brodie MJ. Antiepileptic drug combinations: have newer agents altered clinical outcomes? Epilepsy Res. 2012;98:194\u20138.","journal-title":"Epilepsy Res"},{"key":"698_CR116","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.yebeh.2018.03.002","volume":"82","author":"G Cacao","year":"2018","unstructured":"Cacao G, Parra J, Mannan S, Sisodiya S, Sander J. Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral centre. Epilepsy Behav. 2018;82:81\u20136.","journal-title":"Epilepsy Behav"},{"key":"698_CR117","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00415-004-0521-1","volume":"251","author":"E Trinka","year":"2004","unstructured":"Trinka E, Baumgartner S, Unterberger I, Unterrainer J, Luef G, Haberlandt E, et al. Long-term prognosis for childhood and juvenile absence epilepsy. J Neurol. 2004;251:1235\u201341.","journal-title":"J Neurol"},{"key":"698_CR118","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.seizure.2014.03.002","volume":"23","author":"P Danhofer","year":"2014","unstructured":"Danhofer P, Brazdil M, Oslejskova H, Kuba R. Long-term seizure outcome in patients with juvenile absence epilepsy: a retrospective study in a tertiary referral center. Seizure. 2014;23:443\u20137.","journal-title":"Seizure."},{"key":"698_CR119","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.seizure.2016.09.005","volume":"44","author":"EM Yacubian","year":"2017","unstructured":"Yacubian EM. Juvenile myoclonic epilepsy: challenges on its 60th anniversary. Seizure. 2017;44:48\u201352.","journal-title":"Seizure."},{"key":"698_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.0000000000007771","volume":"93","author":"JG Burneo","year":"2019","unstructured":"Burneo JG. SUDEP: let\u2019s talk about it. Neurology. 2019;93:1\u20132.","journal-title":"Neurology."},{"issue":"Suppl. 9","key":"698_CR121","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1111\/j.1528-1167.2005.00315.x","volume":"46","author":"A Covanis","year":"2005","unstructured":"Covanis A. Photosensitivity in idiopathic generalized epilepsies. Epilepsia. 2005;46(Suppl. 9):67\u201372.","journal-title":"Epilepsia."},{"key":"698_CR122","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.seizure.2014.08.004","volume":"23","author":"AA Asadi-Pooya","year":"2014","unstructured":"Asadi-Pooya AA, Hashemzehi Z, Emami M. Predictors of seizure control in patients with juvenile myoclonic epilepsy (JME). Seizure. 2014;23:889\u201391.","journal-title":"Seizure."},{"key":"698_CR123","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.seizure.2019.06.021","volume":"70","author":"R G\u0171rer","year":"2019","unstructured":"G\u0171rer R, Aydin S, \u0150zkara C. Outcomes of low dose valproic acid treatment in patients with juvenile myoclonic epilepsy. Seizure. 2019;70:43\u20138.","journal-title":"Seizure."},{"key":"698_CR124","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.eplepsyres.2016.10.017","volume":"128","author":"FS Giorgi","year":"2016","unstructured":"Giorgi FS, Guida M, Caciagli L, et al. Social cognition in juvenile myoclonic epilepsy. Epilepsy Res. 2016;128:61\u20137.","journal-title":"Epilepsy Res"},{"key":"698_CR125","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.yebeh.2015.09.024","volume":"53","author":"S Somayajula","year":"2015","unstructured":"Somayajula S, Vooturi S, Jayalakshmi S. Psychiatric disorders among 165 patients with juvenile myoclonic epilepsy in India and association with clinical and sociodemographic variables. Epilepsy Behav. 2015;53:37\u201342.","journal-title":"Epilepsy Behav"},{"key":"698_CR126","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pediatrneurol.2019.03.011","volume":"101","author":"DN Almane","year":"2019","unstructured":"Almane DN, Jones JE, McMillan T, et al. The timing, nature and range of neurobehavioral comorbidities in juvenile myoclonic epilepsy. Pediatr Neurol. 2019;101:47\u201352.","journal-title":"Pediatr Neurol"},{"key":"698_CR127","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.yebeh.2016.03.022","volume":"61","author":"AM Kanner","year":"2016","unstructured":"Kanner AM. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence. Epilepsy Behav. 2016;61:282\u20136.","journal-title":"Epilepsy Behav"},{"key":"698_CR128","unstructured":"FDA Drug Safety Communication. Valproate antiseizure products contraindicated for migraine prevention in pregnant women due to decreased IQ scores in exposed children. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm350684.htm. Accessed 15 Dec 2019."},{"key":"698_CR129","unstructured":"European Medicines Agency. Valproate and related substances. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Valproate_and_related_substances\/human_referral_prac_000032.jsp&mid=WC0b01ac05805c516f. Accessed 15 Dec 2019."},{"key":"698_CR130","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez-Diaz S, Smith CR, Shen A, et al.; North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology. 2012;78:1692\u20139.","DOI":"10.1212\/WNL.0b013e3182574f39"},{"key":"698_CR131","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1136\/jnnp-2013-306318","volume":"85","author":"E Campbell","year":"2014","unstructured":"Campbell E, Kennedy F, Russell A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85:1029\u201334.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"698_CR132","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1212\/WNL.0000000000001182","volume":"84","author":"GA Baker","year":"2015","unstructured":"Baker GA, Bromley RL, Briggs M, et al. IQ at 6\u00a0years after in utero exposure to antiepileptic drugs: a controlled cohort study. Neurology. 2015;84:382\u201390.","journal-title":"Neurology."},{"key":"698_CR133","doi-asserted-by":"publisher","unstructured":"Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11:CD010224. https:\/\/doi.org\/10.1002\/14651858.cd010224.pub2.","DOI":"10.1002\/14651858.cd010224.pub2"},{"key":"698_CR134","doi-asserted-by":"publisher","first-page":"e017248","DOI":"10.1136\/bmjopen-2017-017248","volume":"7","author":"AA Veroniki","year":"2017","unstructured":"Veroniki AA, Rios P, Cogo E, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. 2017;7:e017248. https:\/\/doi.org\/10.1136\/bmjopen-2017-017248.","journal-title":"BMJ Open"},{"key":"698_CR135","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1136\/jnnp-2017-317515","volume":"89","author":"AS Lacey","year":"2018","unstructured":"Lacey AS, Pickrell WO, Thomas RH, Kerr MP, White CP, Rees MI. Educational attainment of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry. 2018;89:736\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"698_CR136","doi-asserted-by":"crossref","unstructured":"Bromley RL, Weston J, Adab N. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database Syst Rev. 2014;10;CD010236.","DOI":"10.1002\/14651858.CD010236.pub2"},{"key":"698_CR137","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1001\/jama.2013.2270","volume":"309","author":"J Christensen","year":"2013","unstructured":"Christensen J, Gronborg TK, Sorensen MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309:1696\u2013703.","journal-title":"JAMA"},{"key":"698_CR138","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.seizure.2016.10.006","volume":"44","author":"RL Bromley","year":"2017","unstructured":"Bromley RL, Baker GA. Fetal antiepileptic drug exposure and cognitive outcomes. Seizure. 2017;44:225\u201331.","journal-title":"Seizure"},{"key":"698_CR139","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/jnnp-2017-317833","volume":"89","author":"B Mostacci","year":"2018","unstructured":"Mostacci B, Bisulli F, Poluzzi E, et al. Emilia-Romagna study on pregnancy and exposure to antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health. J Neurol Neurosurg Psychiatry. 2018;89:983\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"698_CR140","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1136\/jnnp-2018-318386","volume":"89","author":"LF Bech","year":"2018","unstructured":"Bech LF, Polcwiartek C, Kragholm K, et al. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry. 2018;89:1324\u201331.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"698_CR141","doi-asserted-by":"publisher","first-page":"e186606","DOI":"10.1001\/jamanetworkopen.2018.6606","volume":"2","author":"J Christensen","year":"2019","unstructured":"Christensen J, Pedersen L, Sun Y, et al. Association of prenatal exposure to valproate and other antiepileptic drugs with risk for attention-deficit\/hyperactivity disorder in offspring. JAMA Network Open. 2019;2(1):e186606.","journal-title":"JAMA Network Open."},{"key":"698_CR142","first-page":"53","volume":"361","author":"H Angus-Leppan","year":"2018","unstructured":"Angus-Leppan H, Liu R. Weighing the risks of valproate in women who could become pregnant. BMJ. 2018;361:53\u20135.","journal-title":"BMJ"},{"key":"698_CR143","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/WCO.0000000000000659","volume":"32","author":"T Tomson","year":"2019","unstructured":"Tomson T, Battino D, Perucca E. Teratogenicity of antiepileptic drugs. Curr Opin Neurol. 2019;32:246\u201352.","journal-title":"Curr Opin Neurol"},{"key":"698_CR144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1684\/epd.2019.1105","volume":"21","author":"T Tomson","year":"2019","unstructured":"Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord. 2019;21:1\u201321.","journal-title":"Epileptic Disord."},{"key":"698_CR145","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1080\/14656566.2016.1195810","volume":"17","author":"A Rohracher","year":"2016","unstructured":"Rohracher A, Brigo F, Hofler J, et al. Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy. Expert Opin Pharmacother. 2016;17:1403\u201311.","journal-title":"Expert Opin Pharmacother"},{"key":"698_CR146","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1474-4422(18)30495-2","volume":"18","author":"LJ Stephen","year":"2019","unstructured":"Stephen LJ, Harden C, Tomson T, Brodie MJ. Management of epilepsy in women. Lancet Neurol. 2019;18:481\u201391.","journal-title":"Lancet Neurol."},{"key":"698_CR147","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jama.2017.14485","volume":"318","author":"RL Bromley","year":"2017","unstructured":"Bromley RL, Weston J, Marson AG. Maternal use of antiepileptic agents during pregnancy and major congenital malformations in children. JAMA. 2017;318:1700\u20131.","journal-title":"JAMA"},{"key":"698_CR148","doi-asserted-by":"publisher","first-page":"e1228","DOI":"10.1212\/WNL.0000000000006240","volume":"91","author":"PE Voinescu","year":"2018","unstructured":"Voinescu PE, Park S, Chen IQ, et al. Antiepileptic drug clearances during pregnancy and clinical implications for women with epilepsy. Neurology. 2018;91:e1228\u201336.","journal-title":"Neurology."},{"key":"698_CR149","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1212\/01.wnl.0000289511.20864.2a","volume":"70","author":"PB Pennell","year":"2008","unstructured":"Pennell PB, Peng L, Newport DJ, Ritchie JC, Koganti A, Holley DK, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring and seizure frequency. Neurology. 2008;70:2130\u20136.","journal-title":"Neurology."},{"key":"698_CR150","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.yebeh.2012.06.036","volume":"28","author":"B Baykan","year":"2013","unstructured":"Baykan B, Martinez-Juarez IE, Altindag EA, Camfield CS, Camfield PR. Lifetime prognosis of juvenile myoclonic epilepsy. Epilepsy Behav. 2013;28:S18\u201324.","journal-title":"Epilepsy Behav"},{"key":"698_CR151","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.eplepsyres.2014.09.008","volume":"108","author":"J H\u00f6fler","year":"2014","unstructured":"H\u00f6fler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Seizures outcome in 175 patients with juvenile myoclonic epilepsy: a long-term observational study. Epilepsy Res. 2014;108:1817\u201324.","journal-title":"Epilepsy Res"},{"key":"698_CR152","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.seizure.2018.05.015","volume":"59","author":"L Healy","year":"2018","unstructured":"Healy L, Moran M, Singhal S, et al. Relapse after treatment withdrawal of antiepileptic drugs for juvenile absence epilepsy and juvenile myoclonic epilepsy. Seizure. 2018;59:116\u201322.","journal-title":"Seizure."},{"issue":"10","key":"698_CR153","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1007\/s00415-019-09457-z","volume":"266","author":"BJ Vorderwulbecke","year":"2019","unstructured":"Vorderwulbecke BJ, Kirschbaum A, Merkle H, Senf P, Holtkamp M. Discontinuing antiepileptic drugs in long-standing idiopathic generalised epilepsy. J Neurol. 2019;266(10):2554\u20139.","journal-title":"J Neurol"},{"key":"698_CR154","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/ana.24103","volume":"75","author":"M Holtkamp","year":"2014","unstructured":"Holtkamp M, Kowski AB, Merkle H, Janz D. Long-term outcome in epilepsy with grand mal on awakening: forty years of follow-up. Ann Neurol. 2014;75:298\u2013302.","journal-title":"Ann Neurol"},{"key":"698_CR155","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1212\/01.wnl.0000437303.36064.f8","volume":"81","author":"P Senf","year":"2013","unstructured":"Senf P, Schmitz B, Holtkamp M, Janz D. Prognosis of juvenile myoclonic epilepsy 45\u00a0years after onset: seizure outcome and predictors. Neurology. 2013;81:2128\u201333.","journal-title":"Neurology."},{"key":"698_CR156","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","volume":"15","author":"M Keezer","year":"2016","unstructured":"Keezer M, Sisodiya S, Sander J. Comorbidities of epilepsy: current concepts and future perspectives. Lancet Neurol. 2016;15:106\u201315.","journal-title":"Lancet Neurol."},{"key":"698_CR157","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1212\/WNL.0b013e318203e93d","volume":"76","author":"J O\u2019Muircheartaigh","year":"2011","unstructured":"O\u2019Muircheartaigh J, Vollmar C, Barker GJ, et al. Focal structural changes and cognitive dysfunction in juvenile myoclonic epilepsy. Neurology. 2011;76:34\u201340.","journal-title":"Neurology."},{"key":"698_CR158","doi-asserted-by":"publisher","first-page":"106321","DOI":"10.1016\/j.yebeh.2019.05.017","volume":"100","author":"M Yogarajah","year":"2019","unstructured":"Yogarajah M, Mula M. Social cognition, psychiatric comorbidities and quality of life in adults with epilepsy. Epilepsy Behav. 2019;100:106321.","journal-title":"Epilepsy Behav"},{"key":"698_CR159","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1055\/s-0037-1599236","volume":"48","author":"M Rauchenzauner","year":"2017","unstructured":"Rauchenzauner M, Hagn C, Walch R, Baumann M, Haberlandt E, Fr\u00fchwirth M, Rostasy K. Quality of life and fitness in children and adolescents with epilepsy (EpiFit). Neuropediatrics. 2017;48:161\u20135.","journal-title":"Neuropediatrics."},{"key":"698_CR160","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.yebeh.2015.12.018","volume":"55","author":"S Gupta","year":"2016","unstructured":"Gupta S, Kwan P, Faught E, Tsong W, Forsythe A, Ryvlin P. Understanding the burden of idiopathic generalised epilepsy in the United States, Europe and Brazil: an analysis for the National Health and Wellness Survey. Epilepsy Behav. 2016;55:146\u201356.","journal-title":"Epilepsy Behav"},{"key":"698_CR161","first-page":"343","volume-title":"A clinical guide to tpileptic syndromes and their treatment","author":"CP Panayiotopolous","year":"2007","unstructured":"Panayiotopolous CP. Epilepsy with GTCS only. A clinical guide to tpileptic syndromes and their treatment. 2nd ed. London: Springer; 2007. p. 343\u20135.","edition":"2"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-020-00698-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-020-00698-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T18:19:49Z","timestamp":1722363589000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-020-00698-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,25]]},"references-count":161,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["698"],"URL":"https:\/\/doi.org\/10.1007\/s40263-020-00698-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,25]]},"assertion":[{"value":"25 January 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Linda J. Stephen has received personal fees from Eisai, outside of the submitted work. Martin J. Brodie has received personal speaker and\/or consultancy fees from UCB, Eisai, Xenon and Arvelle Therapeutics outside of the submitted work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}